Edgewise Therapeutics gains as genetic disorder drug meets mid-stage study goal

Edgewise Therapeutics

16/12/2024 11:41

** Shares of Edgewise Therapeutics rise about 17% to $32.28
in premarket trading 
    ** Company says its experimental genetic disorder drug met
the main goal in a mid-stage study
    ** The drug, sevasemten, is being developed to treat Becker
Muscular Dystrophy, a rare condition that results in progressive
muscle weakness and degeneration   
    ** Sevasemten helped significantly reduce levels of creatine
kinase, an enzyme associated with skeletal muscle damage in the
study- EWTX
    ** Up to last close, stock more than doubled YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))